Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs) arise from common progenitors. Tumor-derived factors redirect differentiation from immune-promoting DCs to tolerogenic MDSCs, an immunological hallmark of cancer. Indeed, in vitro differentiation of DCs from human primary monocytes results in the generation of MDSCs under tumor-associated conditions (PGE2 or tumor cell-conditioned media). Comparison of MDSC and DC DNA methylomes now reveals extensive demethylation with specific gains of DNA methylation and repression of immunogenic-associated genes occurring in MDSCs specifically, concomitant with increased DNA methyltransferase 3A (DNMT3A) levels. DNMT3A downregulation erases MDSC-specific hypermethylation, and it abolishes their immunosuppressive capacity. Primary MDSCs isolated from ovarian cancer patients display a similar hypermethylation signature in connection with PGE2-dependent DNMT3A overexpression. Our study links PGE2- and DNMT3A-dependent hypermethylation with immunosuppressive MDSC functions, providing a promising target for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
DNA methylation landscapes: Provocative insights from epigenomics
Suzuki, M. M., & Bird, A. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2341 · Cited by 3,039
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
Cited by
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Functions of ROS in Macrophages and Antimicrobial Immunity
Herb, M., & Schramm, M. (2021) · Antioxidants · doi:10.3390/antiox10020313 · Cited by 633
The Role of M1/M2 Macrophage Polarization in Rheumatoid Arthritis Synovitis
Cutolo, M., Campitiello, R., Gotelli, E., & Soldano, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867260 · Cited by 631
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
Finetti, F., Travelli, C., Ercoli, J., Colombo, G., Buoso, E., & Trabalzini, L. (2020) · Biology · doi:10.3390/biology9120434 · Cited by 302
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
Dong, L., Chen, C., Zhang, Y., Guo, P., Wang, Z., Li, J., Liu, Y., Liu, J., Chang, R., Li, Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.016 · Cited by 278
Tolerogenic Dendritic Cells in Autoimmunity and Inflammatory Diseases
Morante-Palacios, O., Fondelli, F., Ballestar, E., & Martínez-Cáceres, E. M. (2021) · Trends in Immunology · doi:10.1016/j.it.2020.11.001 · Cited by 263
Self-citationFuster, J. J., & Walsh, K. (2018) · Circulation Research · doi:10.1161/circresaha.117.312115 · Cited by 162
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012798 · Cited by 112
“…to reduce the differentiation of monocytic MDSC (mMDSCs, Ly6C+Ly6G CD11b+) but not polymorphonuclear MDSC (PMNMDSCs, Ly6CmidLy6G+CD11b+), which is consistent with 4 of 20 EMBO Molecular Medicine 13: e12798 | 2021 ª 2020 The Authors previous studies (Shi et al, 2014; Rodriguez-Ubreva et al, 2017).”
ResultDeterminants, mechanisms, and functional outcomes of myeloid cell diversity in cancer
Caronni, N., Montaldo, E., Mezzanzanica, L., Cilenti, F., Genua, M., & Ostuni, R. (2021) · Immunological Reviews · doi:10.1111/imr.12944 · Cited by 6
Metadata
- Authors
- Rodríguez-Ubreva, J., Català-Moll, F., Obermajer, N., Álvarez-Errico, D., Ramirez, R. N., Company, C., Vento-Tormo, R., Moreno-Bueno, G., Edwards, R. P., Mortazavi, A., Kalinski, P., & Ballestar, E.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 21
- Issue
- 1
- Pages
- 154-167
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2762276342
- Cited by
- 134
- References
- 3
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.